Oral S-ketamine (S-KETPO) is being explored as an alternative to intravenous maintenance treatment (S-KETIV) in treatment-resistant depression (TRD). However, the first-pass effect with S-KETPO significantly alters S-ketamine's bioavailability and the systemic exposure of its active metabolites, raising potential safety and efficacy concerns. This study characterized the pharmacodynamic and...
Recent evidence suggests that NMDA receptor antagonists, such as ketamine, may offer benefit in catatonia. This systematic review was conducted to evaluate the efficacy and safety of ketamine and esketamine for catatonia.